marked.bio

pan-RAF inhibitor · small molecule

naporafenib

2 active trials across 4 of our biomarkers, targeting RAF. Not approved for any biomarker on marked.bio yet.

Also known as LXH254.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 3 Phase 2
EGFR exon 19 deletion / L858R 1 1 Phase 1
KRAS G12C 0 1 –
KRAS G12D 0 2 –

Sponsors

Industry sponsors leading active biomarker-selected trials of naporafenib.

  1. Novartis 2

Trials

2 of 5 trials shown

  1. Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

    Active, not recruiting Phase 2 Novartis Started 2020Primary completion 2027-02 NCT04417621

    naporafenibLTT462trametinib FDA EUribociclib

    Participants with BRAFV600 mutant disease:

    BRAF V600EMelanoma

  2. Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

    Active, not recruiting Phase 1 Novartis Started 2018Primary completion 2026-10 NCT03333343

    nazartinibtrametinibribociclibnaporafenibcapmatinibgefitinib FDA EU

    …tologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.

    EGFR exon 19 deletion / L858REGFR-mutant Non-small Cell Lung Cancer